Related Experiment Video
Updated: Dec 3, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative
Stelliana Goutzamanis1, Joseph S Doyle2, Danielle Horyniak3
1Disease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, VIC, SA, 3004; School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne VIC 3004.
Background:
Little is known about how information on direct-acting antiviral treatment for hepatitis C circulates through peer networks of people who inject drugs. In this study we aimed to explore what and how treatment-related information is shared between people undergoing treatment and their peers.
Methods:
Participants were recruited from two general practice clinics and the community-based hepatitis C Treatment and Prevention Study. Semi-structured interviews were conducted with each participant (N = 20) before, during and following treatment. Interviews explored hepatitis C treatment experiences, key sources of DAA information and the impact of receiving and sharing knowledge. Inductive thematic analysis was conducted. Time sequential matrices were generated to understand thematic change over time.
Results:
Fifty-four interviews were conducted with 20 participants across seven field-sites in Melbourne, Australia. Key themes were: 'peers as a source treatment information', 'do it together' and 'becoming a treatment advocate'. Peers were a crucial trusted source of information. Positive treatment anecdotes were important for building confidence in and motivation to initiate treatment. Many participants adopted a 'treatment advocate' role in their close peer networks, which was described as empowering. Some participants described benefits of undertaking treatment alongside members of their close network.
Conclusion:
Findings illustrate the importance of close peers in shaping treatment perceptions and engagement. This will be important in designing health promotion messaging and interventions to increase treatment uptake.
More Related Videos
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Peripheral Artery Disease III: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care

